Amgen Presents Data from Pivotal Phase 2 Study of BLINCYTOa Immunotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTOa for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia was presented at the 56th American Society of Hematology Annual Meeting and Exposition. In one analysis from the '211 study, 40 percent of patients treated with BLINCYTO who achieved a complete remission or complete remission with partial hematologic recovery were enabled to proceed to allogeneic hematopoietic stem cell transplant .
http://ift.tt/1D1p9Al
http://ift.tt/1D1p9Al
No comments:
Post a Comment